title: DUBs and disease: activity assays for inhibitor development.
abstract: Deubiquitinating enzymes (DUBs) cleave ubiquitin from substrate proteins and so influence the biochemical properties of these proteins, such as their half-life, by a reduction in proteasomal degradation. Several DUBs have been demonstrated to deubiquitinate oncogenic proteins and tumor suppressors, and their activities have been implicated in numerous processes related to disease, including cancer and neurodegeneration. The importance of various DUBs is well established, but the understanding of both their selectivity and reactivity in the ubiquitin-proteasome system is comparatively poor. In this review, the published methods that are available to study DUB action in vitro and their application in finding inhibitors are discussed.
authors: The Netherlands Cancer Institute, Division of Cellular Biochemistry, Plesmanlaan 121, Amsterdam, The Netherlands.
authors: Anitha
authors: A
authors: Shanmugham
authors: Huib
authors: H
authors: Ovaa
mesh_terms: D000818:Animals; D003546:Cysteine Endopeptidases / Q000737:chemistry / Q000378:metabolism*; D015853:Cysteine Proteinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D045726:Metalloproteases / Q000037:antagonists & inhibitors / Q000378:metabolism; D008958:Models, Molecular; D015335:Molecular Probes; D015394:Molecular Structure; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects* / Q000378:metabolism; D011487:Protein Conformation; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D013050:Spectrometry, Fluorescence; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D013678:Technology, Pharmaceutical / Q000379:methods*; D054875:Ubiquitination
chemical_list: D015853:Cysteine Proteinase Inhibitors; D015335:Molecular Probes; D045726:Metalloproteases; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex